EcoDrugPlus

Aldo-Keto Reductase Family 1, Member B1 (Aldose Reductase), Tandem Duplicate 2

Ensembl ID : ENSDARG00000045598
Gene Symbol: AKR1B1.2
17 Enzyme and pathways 5 Cross references
348 Possible Orthologues:

Alpha Glucosidase

Ensembl ID : ENSDARG00000116493
Gene Symbol: GAA
3 Cross references
229 Possible Orthologues:

Alpha-2b Adrenergic Receptor-Like

Ensembl ID : ENSDARG00000116988
Gene Symbol: LOC100330650
5 Cross references
108 Possible Orthologues:

Amine Oxidase Copper Containing 1

Ensembl ID : ENSDARG00000061355
Gene Symbol: AOC1
6 Enzyme and pathways 5 Cross references
233 Possible Orthologues:

Amine Oxidase Copper Containing 2

Ensembl ID : ENSDARG00000014646
Gene Symbol: AOC2
3 Enzyme and pathways 5 Cross references
413 Possible Orthologues:

Amyloid Beta (A4) Precursor Protein A

Ensembl ID : ENSDARG00000104279
Gene Symbol: APPA
5 Cross references
206 Possible Orthologues:

Amyloid Beta (A4) Precursor Protein B

Ensembl ID : ENSDARG00000055543
Gene Symbol: APPB
51 Enzyme and pathways 5 Cross references
205 Possible Orthologues:

Androgen Receptor

Ensembl ID : ENSDARG00000067976
Gene Symbol: AR
22 Enzyme and pathways 5 Cross references
213 Possible Orthologues:

Angiotensin Ii Receptor, Type 1a

Ensembl ID : ENSDARG00000018616
Gene Symbol: AGTR1A
5 Cross references
149 Possible Orthologues:

Angiotensin Ii Receptor, Type 1b

Ensembl ID : ENSDARG00000045443
Gene Symbol: AGTR1B
11 Enzyme and pathways 5 Cross references
203 Possible Orthologues:

Angiotensin Ii Receptor, Type 2

Ensembl ID : ENSDARG00000035552
Gene Symbol: AGTR2
7 Enzyme and pathways 5 Cross references
189 Possible Orthologues:

Apelin Receptor 2

Ensembl ID : ENSDARG00000004447
Gene Symbol: APLNR2
5 Cross references
172 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).